EXORPHIA's Research on Non-invasive Embryo Evaluation Wins Prestigious Award

A Milestone Achievement in Non-Invasive Embryo Evaluation

The collaborative effort spearheaded by EXORPHIA, in conjunction with several esteemed institutions, has achieved recognition at the 44th Annual Meeting of the Japanese Society for Fertilization and Embryo Transfer. Their presentation titled "Non-Invasive Embryo Evaluation through Embryonic Dynamics Analysis: Establishing a Quantitative Evaluation System for Mouse Genetic Variations in Embryonic Development" was honored with the World IVF Congress Memorial Award (Basic). This accolade underlines the importance of innovative methodologies in the evaluation of embryos during in vitro fertilization (IVF) processes.

The Award-Winning Research

Presented by Koki Shimada from Elpixel Co., Ltd on July 30, 2026, the research sought to address the gaps in conventional embryo assessment techniques that rely heavily on morphological characteristics and development speed. While traditional methods provide some insights into embryo viability, they often overlook the internal dynamics that cannot be observed from external appearances. Therefore, there has been a growing demand for objective evaluation methods that impose minimal stress on the embryos.

The research utilizes time-lapse video analysis of mouse embryos to quantify subtle internal movements, termed "embryonic dynamics," in a non-invasive and non-staining manner. By comparing mouse strains with differing embryonic characteristics, the study illustrated how embryonic dynamics could serve as a new framework for evaluating developmental traits distinctively.

This foundational knowledge is pivotal in complementing existing morphological assessments, presenting a pathway to more objective and comprehensive evaluations of embryo conditions.

EXORPHIA's Commitment to Next-Generation IVF Research

EXORPHIA is driven by a commitment to enhance the IVF process through optimization of embryo culture environments using mesenchymal stem cell-derived extracellular vesicles (MSC-EVs). Initial findings from EXORPHIA's research indicate that the introduction of MSC-EVs correlates with an increase in embryonic dynamics, suggesting a potential for improving embryonic viability. Understanding the impact of MSC-EVs on the embryonic development process through non-invasive and quantitative measures is crucial for elucidating mechanisms and objectively assessing their effectiveness.

Building upon the insights garnered from this award-winning evaluation technique, EXORPHIA aims to further explore the relationship between changes in embryonic dynamics induced by MSC-EVs and improvements in embryo quality. This scientific grounding is essential for developing the next generation of IVF technologies.

Future Directions

With an eye on advancement, EXORPHIA plans to pursue collaborations with ART facilities, academia, and tech companies to refine the embryonic dynamics evaluation technology and advance non-clinical and clinical research leveraging MSC-EVs. The focus remains steadfast on quality, safety, and ethics while striving for practical applications of scientifically validated next-generation IVF technologies.

For more information about the 44th Annual Meeting of the Japanese Society for Fertilization and Embryo Transfer, please refer to the official website.

About EXORPHIA

EXORPHIA is a pioneering biotechnology company with a robust foundation in extracellular vesicle (EV) technology. They are dedicated to developing next-generation IVF solutions and advancing practical applications through collaborative development and commercialization of drug-related assets.